Estados financieros detallados de Kura Oncology, Inc. (KURA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 94.7%, margen operativo -411.9%, margen neto -384.3%.
Al precio actual de $11.20, KURA presenta beneficios negativos (P/E no significativo) y un ROE del -207.18%. La capitalización bursátil es de $994M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $53.9M | $67.5M |
| Coste de Ventas | $31000 | $30000 | $10000 | 0 | $194000 | 0 | 0 | $849000 | 0 | $57000 |
| Beneficio Bruto | -$31000 | -$30000 | -$10000 | 0 | -$194000 | 0 | 0 | -$849000 | $53.9M | $67.4M |
| I+D | $20.4M | $26.4M | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115.2M | $170.0M | $251.1M |
| Generales y Administrativos | $8.0M | $9.7M | $16.1M | $19.7M | $31.3M | $46.5M | $47.1M | $50.6M | $77.1M | $120.0M |
| Gastos Operativos | $28.4M | $36.1M | $62.9M | $67.5M | $91.7M | $131.3M | $139.9M | $165.0M | $247.1M | $371.1M |
| Beneficio Operativo | -$28.4M | -$36.1M | -$62.9M | -$67.5M | -$91.9M | -$131.3M | -$139.9M | -$165.8M | -$193.2M | -$303.6M |
| EBITDA | -$28.3M | -$36.0M | -$62.9M | -$67.5M | -$88.9M | -$129.5M | -$134.9M | -$150.2M | -$169.5M | -$275.8M |
| Gastos por Intereses | $577000 | $888000 | $970000 | $580000 | $578000 | $414000 | $229000 | $1.5M | $1.6M | $1.5M |
| Beneficio Antes de Impuestos | -$27.6M | -$35.4M | -$60.4M | -$63.1M | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$172.0M | -$278.4M |
| Impuestos | -$31000 | -$30000 | 0 | 0 | 0 | 0 | 0 | 0 | $2.0M | $297000 |
| Beneficio Neto | -$27.6M | -$35.4M | -$60.4M | -$63.1M | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
| BPA | $-1.47 | $-1.52 | $-1.72 | $-1.51 | $-1.69 | $-1.97 | $-2.03 | $-2.08 | $-2.02 | $-3.18 |
| BPA Diluido | $-1.47 | $-1.52 | $-1.72 | $-1.51 | $-1.69 | $-1.97 | $-2.03 | $-2.08 | $-2.02 | $-3.18 |
| Acciones en Circulación (Diluidas) | $18.7M | $23.2M | $35.2M | $41.9M | $53.1M | $66.4M | $67.0M | $73.2M | $86.2M | $87.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $20.8M | $17.3M | $18.3M | $20.9M |
| Beneficio Bruto | $17.5M | $17.3M | $17.6M | $20.6M |
| Beneficio Operativo | -$80.0M | -$86.3M | -$78.8M | -$73.0M |
| EBITDA | -$74.0M | -$80.2M | -$72.6M | -$65.6M |
| Beneficio Neto | -$74.1M | -$81.0M | -$73.3M | -$68.3M |
| BPA | $-0.85 | $-0.92 | $-0.83 | $-0.77 |
| BPA Diluido | $-0.85 | $-0.92 | $-0.83 | $-0.77 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $9.7M | $11.4M | $16.1M | $26.1M | $325.5M | $90.7M | $51.8M | $37.3M | $224.5M | $149.1M |
| Inversiones a Corto | $58.1M | $81.7M | $162.9M | $210.8M | $307.8M | $427.3M | $386.2M | $386.6M | $502.9M | $518.1M |
| Cuentas por Cobrar | $295000 | $216000 | $224000 | $30000 | 0 | 0 | 0 | 0 | 0 | $12.6M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $413000 |
| Activos Corrientes | $68.8M | $94.6M | $181.2M | $239.6M | $637.3M | $522.3M | $446.4M | $432.5M | $744.8M | $708.7M |
| Inmovilizado Material | $40000 | $10000 | 0 | $278000 | $8.4M | $8.2M | $6.4M | $8.9M | $7.5M | $15.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $69.8M | $95.9M | $182.4M | $242.0M | $647.2M | $534.1M | $456.3M | $448.9M | $760.2M | $738.4M |
| Cuentas por Pagar | $638000 | $1.2M | $3.9M | $3.5M | $2.8M | $3.2M | $1.5M | $2.3M | $1.5M | $5.0M |
| Deuda a Corto | 0 | $1.5M | 0 | $250000 | $3.0M | 0 | 0 | 0 | $2.6M | 0 |
| Pasivos Corrientes | $5.5M | $10.0M | $13.6M | $15.6M | $26.0M | $22.5M | $24.1M | $35.3M | $78.7M | $117.0M |
| Deuda a Largo | $7.3M | $5.6M | $7.5M | $7.2M | $4.2M | 0 | $9.2M | $9.3M | $6.9M | $9.7M |
| Pasivos Totales | $12.9M | $16.0M | $21.4M | $23.2M | $36.3M | $27.4M | $36.0M | $51.7M | $346.5M | $564.2M |
| Reservas | -$53.9M | -$89.3M | -$149.7M | -$212.9M | -$302.5M | -$433.0M | -$568.8M | -$721.4M | -$895.4M | -$1.17B |
| Patrimonio Neto | $56.9M | $79.9M | $161.0M | $218.8M | $610.9M | $506.6M | $420.3M | $397.3M | $413.6M | $174.1M |
| Deuda Total | $7.3M | $7.1M | $7.5M | $7.8M | $15.0M | $6.9M | $14.0M | $17.2M | $16.6M | $20.5M |
| Deuda Neta | -$60.5M | -$86.0M | -$171.5M | -$229.1M | -$618.3M | -$511.1M | -$424.0M | -$406.8M | -$710.8M | -$646.8M |
| Capital Circulante | $63.4M | $84.6M | $167.6M | $224.0M | $611.3M | $499.8M | $422.4M | $397.2M | $666.1M | $591.7M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $95.3M | $149.1M | $39.1M | $70.2M |
| Activos Totales | $649.4M | $738.4M | $652.6M | $587.8M |
| Pasivos Totales | $406.8M | $564.2M | $544.7M | $539.4M |
| Patrimonio Neto | $242.5M | $174.1M | $107.9M | $48.4M |
| Deuda Total | $19.5M | $20.5M | $24.3M | $24.5M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$27.6M | -$35.4M | -$60.4M | -$63.1M | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
| Amortizaciones | $31000 | $30000 | $10000 | 0 | $194000 | $558000 | $759000 | $849000 | $848000 | -$7.5M |
| Compensación en Acciones | $2.1M | $4.5M | $8.7M | $9.4M | $12.8M | $23.6M | $26.3M | $28.1M | $33.9M | $37.1M |
| Cambio en Capital Circulante | -$80000 | $2.6M | $4.4M | $74000 | $6.4M | -$3.2M | -$3.0M | $7.8M | $286.2M | $184.4M |
| Flujo de Caja Operativo | -$25.3M | -$28.4M | -$48.7M | -$54.8M | -$69.8M | -$104.6M | -$110.1M | -$124.8M | $134.3M | -$64.1M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | -$2.2M | -$1.1M | -$626000 | -$168000 | -$472000 | -$6.6M |
| Adquisiciones | 0 | 0 | 0 | 0 | $97765 | $125688 | -$33253 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$25.3M | -$28.4M | -$48.7M | -$54.8M | -$72.0M | -$105.7M | -$110.7M | -$125.0M | $133.8M | -$70.7M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$80.6M | $117.3M | -$85.9M | -$62.5M |
| Inversiones (CapEx) | -$2.6M | -$2.3M | -$128000 | -$656000 |
| Flujo de Caja Libre | -$83.2M | $115.0M | -$86.0M | -$63.2M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $11.0M | $11.4M | $8.4M | $8.2M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | | | | | +25.2% |
| Crecimiento Beneficio Neto (anual) | | -28.6% | -70.6% | -4.5% | -41.9% | -45.6% | -4.1% | -12.4% | -14.0% | -60.2% |
| Crecimiento BPA (anual) | | -3.4% | -13.2% | +12.2% | -11.9% | -16.6% | -3.0% | -2.5% | +2.9% | -57.4% |
| Cambio en Acciones (anual) | | +24.3% | +51.4% | +19.2% | +26.5% | +25.0% | +1.0% | +9.3% | +17.7% | +1.8% |
| Crecimiento FCF (anual) | | -12.2% | -71.1% | -12.5% | -31.5% | -46.8% | -4.7% | -12.9% | +207.1% | -152.8% |
| Margen Bruto | | | | | | | | | 100.0% | 99.9% |
| Margen Operativo | | | | | | | | | -358.5% | -449.9% |
| Margen EBITDA | | | | | | | | | -314.6% | -408.7% |
| Margen Neto | | | | | | | | | -322.9% | -412.9% |
| Margen FCF | | | | | | | | | 248.4% | -104.8% |
| Tasa Impositiva Efectiva | 0.1% | 0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -1.2% | -0.1% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-1.36 | $-1.22 | $-1.38 | $-1.31 | $-1.36 | $-1.59 | $-1.65 | $-1.71 | $1.55 | $-0.81 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $18.7M | $23.2M | $35.2M | $41.9M | $53.1M | $66.4M | $67.0M | $73.2M | $86.2M | $87.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -207.18% |
| Rentabilidad sobre capital invertido | -66.95% |
| Rentabilidad sobre activos | -50.49% |
| Margen bruto | 94.73% |
| Margen operativo | -411.90% |
| Margen neto | -384.30% |
Salud financiera
| Deuda / Patrimonio | 0.50 |
| Ratio corriente | 4.73 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -4.01 | -10.07 | -8.16 | -9.11 | -19.33 | -7.11 | -6.11 | -6.91 | -4.31 | -3.27 |
| P/VC | 1.94 | 4.45 | 3.07 | 2.64 | 2.84 | 1.83 | 1.98 | 2.65 | 1.81 | 5.23 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.93 | 13.50 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 99.9% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -358.5% | -449.9% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -322.9% | -412.9% |